Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 9, 2013, Pages 5263-5267

  Unal, Olcun Umit ^a   Oztop, Ilhan ^b   Unek, Ilkay Tugba ^c   Yilmaz, Ahmet Ugur ^d  

^a ATATURK UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

^c TEPECIK EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^d IZMIR UNIVERSITY   (Turkey)

Author keywords

5 fluorouracil; Gemcitabine; High dose folinic acid; Metastatic biliary tract cancer

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILIARY TRACT TUMOR; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84887591995     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.9.5263     Document Type: Article

References (33)

1. Chen JS, Jan YY, Lin YC, et al (1998). Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas. Anticancer Drugs, 5, 393-7.
2. Cho JY, Paik YH, Chang YS, et al (2005). Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer, 104, 2753-8.
3. Croitoru A, Gramaticu I, Dinu I, et al (2012). Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma-a retrospective study. J Gastrointestin Liver Dis, 21, 277-84.
4. Cunningham D, Chau I, Stocken DD, et al (2005). Phase III randomized comparison of gemcitabine (gem) vs gemcitabine plus capecitabine (Gem-CAP) in patients with advanced pancreatic cancer. Eur J Cancer, 3, 11.
5. Ducreux M, Van Cutsem E, Van Laethem JL, et al (2005). A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer, 41, 398-403.
6. Eckel F, Schmid RM (2007). Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer, 6, 896-902.
7. Falkson G, MacIntyre JM, Moertel CG (1984). Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer, 54, 965.
8. Gebbia V, Majello E, Testa A, et al (1996). Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). Cancer, 78, 1300-7.
9. Gesto DS, Cerqueira NM, Fernandes PA, et al(2012). Gemcitabine: a critical nucleoside for cancer therapy. Curr Med Chem, 19, 1076-87.
10. Glimelius B, Hoffman K, Sjoden PO, et al (1996). Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol, 7, 593-600.
11. Hamdani NH, Qadri SK, Aggarwalla R, et al (2012). Clinicopathological study of gall bladder carcinoma with special reference to gallstones: our 8-year experience from eastern India. Asian Pac J Cancer Prev, 13, 5613-7.
12. Harvey JH, Smith FP, Schein PS (1984). 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol, 2, 1245-8.
13. Iqbal S, Rankin C, Lenz HJ, et al (2011). A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol, 6, 1595-602.
14. Kajanti M, Pyrhonen S (1994). Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol, 17, 223.
15. Kanai M, Yoshimura K, Tsumura T, et al (2011). A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. Cancer Chemother Pharmacol, 67, 1429-34.
16. Kameda R, Ando T, Kobayashi S, et al (2013). A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer. Jpn J Clin Oncol, 6, 636-40.
17. Kim JY, Kim YJ, Lee KW, et al (2013). Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea. Jpn J Clin Oncol, 43,132-8.
18. Lim KH, Han SW, Oh DY, et al (2012). Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer. Oncol, 83, 57-66.
19. Louvet C, Andre T, Hammel P (2001). Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol, 12, 675-9.
20. Okusaka T, Nakachi K, Fukutomi A, et al (2010). Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer, 10, 469-74.
21. Oztop I, Yilmaz U, Yavuzsen T, et al (2004). Gemcitabine combined with infusional 5-Fluorouracil and High-Dose leucovorin for the treatment of advanced carcinoma of the pancreas. Chemotherapy, 50, 127-32.
22. Park JS, Oh SY, Kim SH, et al (2005). Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol, 35, 68-73.
23. Qu K, Liu SN, Chang HL, et al (2012). Gallbladder cancer: a subtype of biliary tract cancer which is a current challenge in China. Asian Pac J Cancer Prev, 13, 1317-20.
24. Santini D, Virzi V, Vasile E, et al (2012). A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients. Oncology, 82, 75-82.
25. Sasaki T, Isayama H, Nakai Y, et al (2010). Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol, 65, 1101-7.
26. Sasaki T, Isayama H, Nakai Y, et al (2011). Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs, 6, 1488-93.
27. Sharma A, Dwary AD, Mohanti BK, et al (2010). Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol, 28, 4581-6.
28. Suzuki E, Furuse J, Ikeda M, et al (2010). Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncol, 79, 39-45.
29. Tan JW, Hu BS, Chu YJ, et al (2013). One-stage resection for bismuth type IV hilar cholangiocarcinoma with high hilar resection and parenchyma-preserving strategies: a cohort study. World J Surg, 3, 614-21.
30. Valle JW, Wasan H, Johnson P, et al (2009). Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study-The UK ABC-01 Study. Br J Cancer, 101, 621-7.
31. Valle J, Wasan H, Palmer DH, et al (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 362, 1273-81.
32. Wagner AD, Buechner-Steudel P, Moehler M, et al (2009). Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials. Br J Cancer, 101,1846-52.
33. Yonemoto N, Furuse J, Okusaka T, et al (2007). A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol, 37, 843-51.